West Pharmaceutical Services (WST) Q2 FY26 earnings call

West Pharmaceutical Services reported strong Q2 FY26 results, exceeding top and bottom-line expectations with 13% organic revenue growth and 29% adjusted EPS growth, driven by robust performance in Proprietary Products, particularly Biologics and HVP components. The company raised its full-year organic revenue guidance and reaffirmed adjusted EPS guidance, reflecting continued momentum and operational excellence, despite facing headwinds from a cyber incident and currency fluctuations. Management highlighted multi-year opportunities in HVP upgrades and GLP-1 therapies, while also navigating a